Patient Benefits

Botulinum toxin type A (BoNT-A) neuromodulation is the most common cosmetic procedure in the United States, with 3.6 million procedures in 2014. While FDA approval is limited to glabellar and lateral canthal lines, its aesthetic use has expanded to include the frontalis, nasalis, and lower face and neck muscles. With increased BoNT-A usage, assessing patient satisfaction becomes crucial for optimizing outcomes.

Previous studies show high patient satisfaction post-BoNT-A treatment, but evaluation methods vary, including single-question assessments and comprehensive surveys like the Facial Line Treatment Satisfaction Questionnaire. These surveys explore facets such as youthfulness, attractiveness, confidence, and psychosocial well-being due to facial appearance.